Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds
CRANBURY, N.J., Dec. 16, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity


